Literature DB >> 10627636

Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis.

A Sureda1, J Petit, S Brunet, C Boqué, A Aventín, R Martino, J R González, B Amill, I Larriba, A Blanco, G A Martín-Henao, J Sierra, A Grañena.   

Abstract

Between April 1996 and May 1998, 20 consecutive patients with Ph chromosome-positive CML in first chronic phase without an HLA-identical sibling received the mini-ICE regimen shortly after diagnosis to mobilize progenitor cells into the peripheral blood (PBPCs). The sex distribution was 12 males and eight females and the median (range) age 48.5 (22-62) years. The time interval between diagnosis and mobilization was a median (range) of 2 (0-5) months. Leukaphereses were initiated during recovery from chemotherapy-induced aplasia. A median number of 3 (1-7) aphereses per patient were performed to collect >/=2.0 x 106 CD34+cells/kg. Cytogenetic analysis was performed on the aphereses products of 18 patients. Complete cytogenetic Ph chromosome negativity was observed in four patients, nine had a partial negativity, three a minimal negativity and two no negative cells. Southern blot for bcr-abl was negative in the remaining two patients but the polymerase chain reaction analysis was positive. Following reinfusion, severe neutropenia was present for a median of 8.5 (3-19) days and severe thrombocytopenia lasted a median of 8 (3-18) days. Ten patients did not develop febrile neutropenia with four of them being treated on an outpatient basis. Treatment-related mortality was not observed. In conclusion, our experience demonstrates the feasibility of mobilizing PBPCs shortly after the diagnosis of CML with a safe regimen. Of note, mini-ICE allowed the collection of apheresis products with at least a major component of Ph-negative cells in almost 75% of the patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10627636     DOI: 10.1038/sj.bmt.1702068

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.

Authors:  Roman Hájek; Daniela Zácková; Tomás Büchler; Miroslav Penka; Eva Krahulcová; Zdenĕk Korístek; Jaroslava Vinklárková; Jiri Adler; Eva Janovská; Karel Indrák; Edgar Faber; Michal Doubek; Martin Klabusay; Alexandra Oltová; Petr Kuglík; Ludmila Bourková; Ladislav Dusek; Iveta Mareschová; Jiri Mayer; Jiri Vorlícek
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

2.  Mobilization and collection of CD34(+) cells for autologous transplantation of peripheral blood hematopoietic progenitor cells in children: analysis of two different granulocyte-colony stimulating factor doses.

Authors:  Kátia Aparecida de Brito Eid; Eliana Cristina Martins Miranda; Simone Dos Santos Aguiar
Journal:  Rev Bras Hematol Hemoter       Date:  2015-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.